Press release
Immune Thrombocytopenia Therapeutics Market Size (7MM) was ~USD 4,000 Million in 2025 and It is projected to grow by 2036, estimates DelveInsight
Immune Thrombocytopenia Market
Unlock detailed insights into the Immune Thrombocytopenia Market by downloading the comprehensive report from DelveInsight @ https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Immune Thrombocytopenia Market Report
• In 2025, the total cases of ITP were approximately 187,800 cases in the 7MM, which is expected to increase by 2036.
• Among the 7MM, the US accounted for the most prevalent cases of ITP, compared to EU4 and the UK, and Japan.
• Among EU4 and the UK, the highest number of cases of ITP were found in the UK, i.e., around 28,000 cases in 2025, whereas Spain accounted for the least cases.
• In Japan, among gender-specific ITP cases, female accounted for approximately 14,000 cases, while male reported 8,200 cases, in 2025.
• The leading Immune Thrombocytopenia Companies such as Rigel Pharmaceuticals, Kissei Pharmaceutical, Grifols, Sobi (Dova Pharmaceuticals), Asahi Kasei Pharma, Amgen, Argenx, Grifols (Biotest), Zenyaku Kogyo, Chugai Pharmaceutical, Novartis, Sanofi/Principia Biopharma, GC Pharma, UCB Biopharma, Takeda (Millennium Pharmaceuticals), Pfizer, Genosco and Oscotec, Vertex/Alpine Immune Sciences, Sanofi/ Bioverativ company, and others.
• Promising Immune Thrombocytopenia Pipeline Therapies such as Huaiqihuang Granule, Avatrombopag, BT595, Romiplostim, Hetrombopag, Rilzabrutinib, SKI-O-703, Eltrombopag, TQB3473 Tablets, and others.
Gain a competitive edge in the Immune Thrombocytopenia Market by exploring our in-depth analysis @ https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Immune Thrombocytopenia Epidemiology Segmentation in the 7MM
• Total Immune Thrombocytopenia Prevalent Cases
• Immune Thrombocytopenia Age-specific Diagnosed Prevalent Cases
• Immune Thrombocytopenia Gender-specific Diagnosed Prevalent Cases
Download the report to understand which factors are driving Immune Thrombocytopenia Epidemiology Trends @ https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Marketed Immune Thrombocytopenia Drugs
• TAVALISSE (fostamatinib): Rigel Pharmaceuticals/Kissei Pharmaceutical
Fostamatinib disodium (also known as TAVALISSE; R-985788) is an orally bioavailable investigational agent developed by Rigel Pharmaceuticals and approved for treating patients suffering from persistent/chronic adult idiopathic thrombocytopenic purpura. It inhibits FcR-triggered, SYK-dependent cytoskeletal rearrangement during phagocytosis. As stated by Rigel Pharmaceuticals, fostamatinib has a unique mechanism of action, blocking IgG receptor signaling in both macrophages and B cells via SYK kinase. It was approved by the US FDA in April 2018.
• DOPTELET (avatrombopag): Sobi (Dova Pharmaceuticals)
DOPTELET is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic Immune Thrombocytopenia who have had an insufficient response to previous treatment. In June 2019, the US FDA approved Dova Pharmaceuticals' supplemental New Drug Application (sNDA) for expanding DOPTELET use. The drug is indicated for the treatment of thrombocytopenia in adults with chronic Immune Thrombocytopenia who have had an insufficient response to a previous treatment.
Emerging Immune Thrombocytopenia Drugs
• Ianalumab (VAY736): Novartis
Ianalumab is a novel, fully human immunoglobulin G1 monoclonal antibody that targets the BAFF receptor and has a unique dual mechanism of action. Currently, ianalumab is in Phase III of the clinical trial for 1st and 2nd line treatment of ITP. As of December 2025, Novartis intends to submit the VAYHIT2 data from the Phase III study together with upcoming results from the ongoing first-line ITP trial (VAYHIT1) for regulatory review in 2027.
• Mezagitamab: Millennium Pharmaceuticals/Takeda
Mezagitamab is a subcutaneously administered human monoclonal antibody (human IgG1 lambda) that binds to the CD38 transmembrane glycoprotein expressed on the surface of cells and can deplete those cells by distinct mechanisms.
Discover key developments and opportunities in the Immune Thrombocytopenia Market @ https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Immune Thrombocytopenia Companies
Rigel Pharmaceuticals, Kissei Pharmaceutical, Grifols, Sobi (Dova Pharmaceuticals), Asahi Kasei Pharma, Amgen, Argenx, Grifols (Biotest), Zenyaku Kogyo, Chugai Pharmaceutical, Novartis, Sanofi/Principia Biopharma, GC Pharma, UCB Biopharma, Takeda (Millennium Pharmaceuticals), Pfizer, Genosco and Oscotec, Vertex/Alpine Immune Sciences, Sanofi/ Bioverativ company, and others.
Immune Thrombocytopenia Market Outlook
The need to avoid the less effective immune suppressants has led to the development of new more targeted treatments for Immune Thrombocytopenia, starting with the second-generation TPO-RAs and now including SYK inhibition with other classes of treatment in clinical development. The introduction of these novel therapies has allowed to use of less immune suppression in Immune Thrombocytopenia management. Over the last decade, there has been a shift away from immune suppression for the treatment of Immune Thrombocytopenia.
Download DelveInsight's Immune Thrombocytopenia Market report today and stay ahead in this rapidly evolving field. @ https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Immune Thrombocytopenia Market Report
• Coverage- 7MM
• Study Period- 2022-2036
• Immune Thrombocytopenia Companies- Rigel Pharmaceuticals, Kissei Pharmaceutical, Grifols, Sobi (Dova Pharmaceuticals), Asahi Kasei Pharma, Amgen, Argenx, Grifols (Biotest), Zenyaku Kogyo, Chugai Pharmaceutical, Novartis, Sanofi/Principia Biopharma, GC Pharma, UCB Biopharma, Takeda (Millennium Pharmaceuticals), Pfizer, Genosco and Oscotec, Vertex/Alpine Immune Sciences, Sanofi/ Bioverativ company, and others.
• Immune Thrombocytopenia Pipeline Therapies- Huaiqihuang Granule, Avatrombopag, BT595, Romiplostim, Hetrombopag, Rilzabrutinib, SKI-O-703, Eltrombopag, TQB3473 Tablets, and others.
• Immune Thrombocytopenia Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Immune Thrombocytopenia Unmet Needs, KOL's views, Analyst's views, Immune Thrombocytopenia Market Access and Reimbursement
Table of Contents
1. Key Insights
2. Immune Thrombocytopenia Market Report Introduction
3. Country-wise Immune Thrombocytopenia Market Overview at a Glance
4. Immune Thrombocytopenia Market Overview by Therapeutic Class
5. Methodology of Immune Thrombocytopenia Epidemiology and Market
6. Immune Thrombocytopenia Executive Summary
7. Key Events
8. Immune Thrombocytopenia Disease Background and Overview
9. Immune Thrombocytopenia Epidemiology and Patient Population
10. Immune Thrombocytopenia Patient Journey
11. Immune Thrombocytopenia Marketed Drugs
12. Immune Thrombocytopenia Emerging Drugs
13. Immune Thrombocytopenia: Market Analysis
14. Key Opinion Leaders' Views
15. Immune Thrombocytopenia SWOT Analysis
16. Immune Thrombocytopenia Unmet needs
17. Immune Thrombocytopenia Market Access and Reimbursement
18. Appendix
19. Immune Thrombocytopenia Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Immune Thrombocytopenia Therapeutics Market Size (7MM) was ~USD 4,000 Million in 2025 and It is projected to grow by 2036, estimates DelveInsight here
News-ID: 4467846 • Views: …
More Releases from DelveInsight Business Research LLP
The Myeloproliferative Disorder Treatment Market Size is estimated to grow at a …
DelveInsight's Myeloproliferative Disorder Treatment Market Insights Report 2032 provides the current and forecast market analysis, individual leading Myeloproliferative Disorder Treatment Companies market shares, challenges, Myeloproliferative Disorder Treatment Market Drivers, barriers, trends, and key market Myeloproliferative Disorder Treatment companies in the market.
To read more about the latest highlights related to the Myeloproliferative Disorder Treatment Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/myeloproliferative-disorder-treatment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from…
The Dermal Fillers Market Size is estimated to grow at a CAGR of 8.25% by 2032, …
DelveInsight's Dermal Fillers Market Insights Report 2032 provides the current and forecast market analysis, individual leading Dermal Fillers Companies market shares, challenges, Dermal Fillers Market Drivers, barriers, trends, and key market Dermal Fillers companies in the market.
To read more about the latest highlights related to the Dermal Fillers Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/dermal-fillers-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Dermal Fillers Market Report
• In…
The Amniotic Membrane Market Size is estimated to grow at a CAGR of 7.33% by 203 …
DelveInsight's Amniotic Membrane Market Insights Report 2032 provides the current and forecast market analysis, individual leading Amniotic Membrane Companies market shares, challenges, Amniotic Membrane Market Drivers, barriers, trends, and key market Amniotic Membrane companies in the market.
To read more about the latest highlights related to the Amniotic Membrane Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/amniotic-membrane-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Amniotic Membrane Market Report
• In…
The Motor Neuron Disease Treatment Market Size is estimated to grow at a CAGR of …
DelveInsight's Motor Neuron Disease Treatment Market Insights Report 2032 provides the current and forecast market analysis, individual leading Motor Neuron Disease Treatment Companies market shares, challenges, Motor Neuron Disease Treatment Market Drivers, barriers, trends, and key market Motor Neuron Disease Treatment companies in the market.
To read more about the latest highlights related to the Motor Neuron Disease Treatment Market, get a snapshot of the key highlights entailed in the Market…
More Releases for Immune
Immune Probiotic Supplement Market Reviews: What Works Best for Gut and Immune S …
The Global Immune Probiotic Supplement Market reached US$ 68.73 Billion in 2024 and is projected to witness lucrative growth by reaching up to US$ 133.08 Billion by 2032. The Global Immune Probiotic Supplement Market is expected to exhibit a CAGR of 8.61% during the forecast period 2024-2032.
Immune Probiotic Supplement Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges.…
Decoding the Immune System: Immune Repertoire Sequencing Market Unleashes Insigh …
The Immune Repertoire Sequencing Market is likely to grow voraciously, i.e. at a CAGR of 7.3% between 2018-2026. Augmented and virtual reality are abreast with advanced technologies on a significant count. VR and AR do have loads of potential for offering in the healthcare vertical. The application areas include surgery and training simulation, and patients care and treatment.
Persistence Market Research (PMR) delivers the key insights on the immune repertoire sequencing…
Immune health supplement Market - Guardian of health: Supporting immune strength …
Newark, New Castle, USA: The "Immune health supplement Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Immune health supplement Market: https://www.growthplusreports.com/report/immune-health-supplement-market/7978
This latest report researches the industry structure,…
Immune Checkpoint Inhibitors Market: Current Evidence And Future Perspectives Of …
Stratagem Market Insights delivers key insights for the Immune Checkpoint Inhibitors market in its published report, which include global industry analysis, Size, Growth, Opportunities, Emerging Trends, Challenges, and Geographic Regions over the forecast period (2021-2028). In terms of revenue, the global Immune Checkpoint Inhibitors market is projected to grow at a CAGR of XX% during the forecast period, owing to several factors about which SMI offers detailed insights and forecasts…
Immune Checkpoint Inhibitor
Immune Checkpoint Inhibitors Market Insights 2019, Global and Chinese Scenario is a professional and indepth study on the current state of the global Immune Checkpoint Inhibitors industry with a focus on the Chinese market. The report provides key statistics on the market status of the Immune Checkpoint Inhibitors manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Overall, the report provides an…
Immune Health Supplements: Best Way to Boost Your Immune System
ResearchMoz include new market research report "Global Immune Health Supplements Market Research Report 2019" to its huge collection of research reports.
Immune Health Supplements refer to the product which could improve human immune health.
The global Immune Health Supplements market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
Learn more Through Sample Report…
